Qizhong Lu
YOU?
Author Swipe
View article: A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity
A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity Open
The poor prognosis of patients with recurrent or refractory T cell malignancies emphasizes the need for improved immunotherapies. CD5 is a characteristic marker of malignant T cells and is expressed on almost all normal T cells. Therefore,…
View article: CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia
CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia Open
Background: Autologous chimeric antigen receptor T (CAR-T) cell therapy has demonstrated efficacy in the treatment of acute myeloid leukemia (AML). Nevertheless, the intrinsic characteristics of autologous therapy, such as extended manufac…
View article: UCHL1 regulates adiponectin receptors in Sertoli cells to maintain testicular homeostatic balance
UCHL1 regulates adiponectin receptors in Sertoli cells to maintain testicular homeostatic balance Open
View article: Prognostic Value of Centrosome Replication-Related Genes in Prostate Cancer Based on Transcriptomic and Mendelian Randomization
Prognostic Value of Centrosome Replication-Related Genes in Prostate Cancer Based on Transcriptomic and Mendelian Randomization Open
Prostate cancer (PCa) is a significant global health concern, with its incidence and mortality rates projected to rise due to population aging. In this study, we utilized PCa transcriptome data from public databases and applied bioinformat…
View article: Figure S6 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S6 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 6. SLC3A2/PD-L1 BsADC inhibited tumor growth efficacy in SNU-899 xenograft models (A), NCI-H460 xenograft models (B), and A375 xenograft models (C), with or without human PBMCs engraftment in vivo. D, H&E staini…
View article: Figure S2 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S2 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 2. Specific targeting of anti-SLC3A2 19G4 mAb and anti-PD-L1 mAb. A, Sequencing results for HeLa SLC3A2KO cells using CRISPR/Cas9 technology. B, Flow cytometry analysis of 19G4 mAb specific binding to SLC3A2…
View article: Figure S5 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S5 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 5. Flow cytometry analysis for apoptosis. A, Flow cytometric analysis for cell apoptosis in SNU-899 cells. B, Flow cytometric analysis for cell apoptosis in H460 cells. C, Flow cytometric analysis for cel
View article: Table S1 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Table S1 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Table 1. The expression profile of SLC3A2 and PD-L1 on surface of tumor cell lines.
View article: Figure S3 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S3 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 3. SLC3A2/PD-L1 BsAb showed Neutralizing activities and T cells activation. A, SLC3A2/PD-L1 BsAb blocked the interaction between PD-L1-His and biotinylated PD-1-His protein by ELISA. IC50, half-maximal inhibitory conce…
View article: Figure S7 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S7 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 7. Molecular structure of SLC3A2/PD-L1 BsADC. VcMMAE, mc-vc-PAB-MMAE. Drug payload, MMAE, monomethyl auristatin E; Linker, mc-vc-PAB, maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl.
View article: Table S2 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Table S2 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Table 2. The sequence of 19G4 antibody.
View article: Figure S1 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S1 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 1. DepMap database of Expression Public 23Q2 identify co-expression of SLC3A2 and PD-L1 in numerous cell lines.
View article: Supplementary Methods from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Supplementary Methods from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Preparation and characterization of the antibody-drug conjugates
View article: Figure S4 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Figure S4 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Supplementary Figure 4. LC-MS analysis and average DAR value of antibody-drug conjugates. A, LC-MS analysis of SLC3A2/PD-L1 BsADC. LC-MS, liquid chromatography-MS. The average DAR of SLC3A2/PD-L1 BsADC was 0.82. B, LC-MS analysis of SLC3A2…
View article: Data from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Data from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors Open
Bispecific antibodies (BsAb) and antibody-drug conjugates (ADC) have shown significant promise in cancer treatment, enhancing drug selectivity and therapeutic efficacy as demonstrated in multiple clinical studies. Bispecific antibody-drug …
View article: mRNA‐Engineered CD5‐CAR‐γδT<sup>CD5‐</sup> Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia
mRNA‐Engineered CD5‐CAR‐γδT<sup>CD5‐</sup> Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia Open
Clinical trials of Chimeric Antigen Receptor T‐cell (CAR‐T) therapy have demonstrated remarkable success in treating both solid tumors and hematological malignancies. Nanobodies (Nbs) have emerged as promising antigen‐targeting domains for…
View article: Multiple myeloma: signaling pathways and targeted therapy
Multiple myeloma: signaling pathways and targeted therapy Open
Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of M…
View article: Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy
Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy Open
Recent studies have indicated that combining oncolytic viruses with CAR-T cells in therapy has shown superior anti-tumor effects, representing a promising approach. Nonetheless, the localized delivery method of intratumoral injection poses…
View article: BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma Open
View article: A multi-omics analysis of viral nucleic acid poly(I:C) responses to mammalian testicular stimulation
A multi-omics analysis of viral nucleic acid poly(I:C) responses to mammalian testicular stimulation Open
The male reproductive system has a standard immune response regulatory mechanism, However, a variety of external stimuli, including viruses, bacteria, heat, and medications can damage the testicles and cause orchitis and epididymitis. It h…
View article: Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma Open
Multiple myeloma (MM) remains a challenging hematologic malignancy despite advancements in chimeric antigen receptor T-cell (CAR-T) therapy. Current targets of CAR-T cells used in MM immunotherapy have limitations, with a subset of patient…
View article: A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy
A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy Open
View article: Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection
Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection Open
View article: Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma
Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma Open
A craniopharyngioma (CP) is a rare epithelial tumor of the sellar and parasellar region. CPs are difficult to treat due to their anatomical proximity to critical nervous structures, which limits the ability of the surgeon to completely res…
View article: Ubiquitin C‐terminal hydrolase L1 (UCHL1), a double‐edged sword in mammalian oocyte maturation and spermatogenesis
Ubiquitin C‐terminal hydrolase L1 (UCHL1), a double‐edged sword in mammalian oocyte maturation and spermatogenesis Open
Background Recent studies have shown that ubiquitin‐mediated cell apoptosis can modulate protein interaction and involve in the progress of oocyte maturation and spermatogenesis. As one of the key regulators involved in ubiquitin signal, u…
View article: CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma
CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma Open
View article: Development of nanobody-horseradish peroxidase-based sandwich ELISA to detect Salmonella Enteritidis in milk and in vivo colonization in chicken
Development of nanobody-horseradish peroxidase-based sandwich ELISA to detect Salmonella Enteritidis in milk and in vivo colonization in chicken Open
View article: Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein Open
View article: Development of Multivalent Nanobodies Blocking SARS CoV 2 Infection by Targeting RBD of Spike Protein
Development of Multivalent Nanobodies Blocking SARS CoV 2 Infection by Targeting RBD of Spike Protein Open
Background: The outbreak and pandemic of coronavirus SARS CoV 2 caused significant threaten to global public health and economic consequences. It is extremely urgent that global people must take actions to develop safe and effective preven…
View article: Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays
Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays Open